Disorders of Consciousness in Hospitalized Patients with COVID-19: The Role of the Systemic Inflammatory Response Syndrome
- 28 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neurocritical Care
- Vol. 36 (1), 89-96
- https://doi.org/10.1007/s12028-021-01256-7
Abstract
Background Prevalence and etiology of unconsciousness are uncertain in hospitalized patients with coronavirus disease 2019 (COVID-19). We tested the hypothesis that increased inflammation in COVID-19 precedes coma, independent of medications, hypotension, and hypoxia. Methods We retrospectively assessed 3203 hospitalized patients with COVID-19 from March 2 through July 30, 2020, in New York City with the Glasgow Coma Scale and systemic inflammatory response syndrome (SIRS) scores. We applied hazard ratio (HR) modeling and mediation analysis to determine the risk of SIRS score elevation to precede coma, accounting for confounders. Results We obtained behavioral assessments in 3203 of 10,797 patients admitted to the hospital who tested positive for SARS-CoV-2. Of those patients, 1054 (32.9%) were comatose, which first developed on median hospital day 2 (interquartile range [IQR] 1–9). During their hospital stay, 1538 (48%) had a SIRS score of 2 or above at least once, and the median maximum SIRS score was 2 (IQR 1–2). A fivefold increased risk of coma (HR 5.05, 95% confidence interval 4.27–5.98) was seen for each day that patients with COVID-19 had elevated SIRS scores, independent of medication effects, hypotension, and hypoxia. The overall mortality in this population was 13.8% (n = 441). Coma was associated with death (odds ratio 7.77, 95% confidence interval 6.29–9.65) and increased length of stay (13 days [IQR 11.9–14.1] vs. 11 [IQR 9.6–12.4]), accounting for demographics. Conclusions Disorders of consciousness are common in hospitalized patients with severe COVID-19 and are associated with increased mortality and length of hospitalization. The underlying etiology of disorders of consciousness in this population is uncertain but, in addition to medication effects, may in part be linked to systemic inflammation.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (R01 NS106014, R03 NS112760)
- James McDonnel Foundation
This publication has 36 references indexed in Scilit:
- The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findingsBrain, 2020
- Neurological associations of COVID-19The Lancet Neurology, 2020
- COVID‐19: A Global Threat to the Nervous SystemAnnals of Neurology, 2020
- Neurologic Features in Severe SARS-CoV-2 InfectionThe New England Journal of Medicine, 2020
- Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, ChinaJAMA Neurology, 2020
- Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort studyThe Lancet, 2020
- Neurological Implications of COVID-19 InfectionsNeurocritical Care, 2020
- COVID-19: ICU delirium management during SARS-CoV-2 pandemicCritical Care, 2020
- Detection of Brain Activation in Unresponsive Patients with Acute Brain InjuryThe New England Journal of Medicine, 2019
- Mortality associated with withdrawal of life-sustaining therapy for patients with severe traumatic brain injury: a Canadian multicentre cohort studyCMAJ : Canadian Medical Association Journal, 2011